Tisagenlecleucel (Kymriah®) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||28/06/2022|
|Rapid review completed||27/07/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.|